Cash-pay GLP-1 pricing comparison — what worked for you?

anders_CPH said:

Dr.GastroMayo said: ...compounded vs brand cost and coverage...

Bookmarking. The distinction being drawn above is the one nobody else makes. I will report back once I have actually tried it.

Adding the clinical framing, because it changes how the question reads.

Telehealth prescriber review for cost and coverage: I've used 2 different telehealth platforms to get my GLP-1 prescription. Comparison:

I settled on the one that required labs — it shows they care about safety, not just prescribing volume.

julia.endo said:

My insurance denied my PA related to cost and coverage.

julia.endo said:

...my insurance denied cost and coverage coverage because...

Insurance denial is the single biggest barrier to GLP-1 access. Let me share the appeal framework that worked for me and several community members:

1. Document medical necessity (BMI, comorbidities, failed alternatives)
2. Reference clinical practice guidelines (AGA, AACE, Endocrine Society)
3. Cite cost-effectiveness data (preventing diabetes/surgery saves money long-term)
4. Request peer-to-peer review between your doctor and the plan's medical director
5. File external appeal with your state insurance department if internal appeal fails

Don't accept the first denial. The appeal process exists for a reason.

TrialTracker_MD said:

Denials are usually procedural rather than clinical, and the order that works reflects that.

Insurance coverage hack for cost and coverage: if your insurance denies brand Wegovy/Ozempic, consider these alternatives:

1. Prior authorization appeal with peer-to-peer review
2. Manufacturer copay card (for commercial insurance)
3. Patient assistance programs (Novo Nordisk, Eli Lilly)
4. Compounded medication from a 503B pharmacy ($130/month)
5. Canadian pharmacy (requires prescription, ~40-60% savings)

Don't let cost prevent access to effective treatment. There are options at every price point.

Moderator note: the sourcing question belongs in the vendor section and has been split out. Tagging this one for the weekly digest.